BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only potentially curative treatment option for relapsed follicular lymphoma (FL), yet questions remain about the optimal timing. This study analyzed long-term outcomes and associated factors among recipients of allo-HCT with FL. METHODS: Patients with relapsed FL who underwent allo-HCT from 2001 to 2011 with a human leukocyte antigen (HLA)-matched donor were included. Outcome analyses for overall survival (OS), progressionfree survival (PFS), transplant-related mortality (TRM), and disease relapse/progression were calculated. A multivariate analysis was performed to determine factors associated with outcomes, and a prognostic score for treatment failure was developed in a subset analysis of patients. RESULTS: In all, 1567 patients with relapsed FL were included; the median follow-up was 55 months. The 5-year probabilities of OS and PFS were 61% and 52%, respectively. The 5-year cumulative incidences of disease progression/relapse and TRM were 29% and 19%, respectively. Chemoresistant disease, older age, heavy pretreatment, poor performance status (PS), and myeloablative protocols were predictors for worse survival. The prognostic score, using age, lines of prior therapy, disease status, and PS, stratified patients into 3 groups-low, intermediate, and high risk-with 5-year PFS rates of 68%, 53%, and 46%, respectively, and 5-year OS rates of 80%, 62%, and 50%, respectively. CONCLUSIONS: Allo-HCT should be considered for patients with relapsed FL and available HLA-matched donors. Outcomes are better in earlier phases of the disease, and reduced-intensity conditioning should be preferred. The prognostic score presented here can assist in counseling patients and determining the time to proceed to transplantation.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only potentially curative therapy for patients with relapsed follicular lymphoma (FL) despite the introduction of novel agents. Allo-HCT is often associated with lower disease relapse rates than autologous hematopoietic cell transplantation (auto-HCT), but transplant-related mortality (TRM) offsets this benefit. 1 Retrospective analyses [2] [3] [4] comparing auto-HCT and allo-HCT as the first transplant procedure indicate that long-term disease control might favor allo-HCT because of a higher relapse risk in the autograft population not compensated by the well-described higher TRM of the allogeneic procedure. Advances in supportive care, the use of reduced-intensity conditioning (RIC) regimens, and better unrelated donor selection have resulted in the increasing use of allo-HCT in FL. The use of RIC [5] [6] [7] has yet to be shown to be superior to myeloablative regimens (myeloablative conditioning [MAC] regimens) 8 ; however, it allows patients who are otherwise not candidates for allo-HCT to undergo this procedure. The further expansion of the number of candidates for allo-HCT is limited by the availability of human leukocyte antigen (HLA)-matched donors. Unrelated donor hematopoietic stem cell transplantation (URD-HCT) for lymphomas is also associated with long-term disease control. Recipients of URD-HCT often have more advanced disease at the time of transplantation. 9, 10 Despite all this, the timing of transplantation and the optimal patient population still remain to be defined; moreover, prognostic models able to predict allo-HCT outcomes for this histology are not currently available.
To better ascertain the role of allo-HCT in patients with relapsed FL, we have conducted a retrospective analysis including the largest cohort of patients ever studied from both international registries, the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR); a prognostic score for treatment failure has also been developed to guide clinical decisions in our daily medical practice.
MATERIALS AND METHODS

Data Sources
The study was performed through a collaboration between the EBMT and CIBMTR lymphoma disease committees. The EBMT is a voluntary organization comprising 640 transplant centers, mainly in Europe. Accreditation as a member center requires the submission of a Minimal Essential Data A form from all consecutive patients to a central registry. Since 1996, accredited EBMT centers have been subject to onsite audits. Informed consent was obtained locally according to regulations applicable at the time of transplantation. Since January 2003, all transplant centers have been required to obtain written informed consent before data registration according to the Declaration of Helsinki of 1975. The CIBMTR is a voluntary working group of more than 450 transplant centers worldwide that contribute detailed data on consecutive hematopoietic cell transplantation (HCT) to a statistical center located at the Medical College of Wisconsin in Milwaukee and the National Marrow Program Coordinating Center in Minneapolis. The CIBMTR collects data at 2 levels: transplant essential data for all patients and more comprehensive data (Comprehensive Report Forms [CRFs]) for a subset of patients. The CIBMTR-CRF data set was chosen to be used in the study so that we would have more disease-specific information for analysis. Of the 1112 patients who fulfilled the eligibility requirements for this study from the CIBMTR, 452 who were reported in CRFs were included.
Patient Eligibility
Patients with relapsed FL who received a transplant from an HLA-matched sibling or underwent URD-HCT from January 2001 to December 2011 and were reported to the EBMT or CIBMTR (CRF) were included. Patients with transformed FL, umbilical cord blood, haploidentical stem cell transplants, or ex vivo T cell-depleted grafts and those for whom tandem HCT was preplanned were excluded.
Outcomes and Definitions
Histology was based on data reported to both registries. Conditioning regimens were defined as MAC or RIC according to previously established definitions. 11 The disease response was evaluated according to Cheson et al's criteria. 12 Relapse or progression was considered to be chemosensitive if at least partial remission was achieved after the last course of chemotherapy before allo-HCT.
Grade 2 to 4 acute graft-versus-host disease (GVHD) was defined according to standard criteria. 13 Chronic GVHD was determined by the treating physician. The performance status (PS) was defined according to the Karnofsky score criteria (Karnofsky PS).
In the URD-HCT group, donor-recipient pairs were selected in the well-matched category according to Weisdorf et al 14 ; this included high-resolution matching at HLA-A, HLA-B, HLA-C, and HLA-DRB1 (8 of 8).
The primary outcomes after allo-HCT included the following: incidences of acute and chronic GVHD; TRM, which was defined as any death within the first 28 days of transplantation or any death occurring after day 28 in the absence of overt disease progression; relapse/progression, which was defined as the progression or recurrence of FL; progression-free survival (PFS), which was defined as survival without recurrence or tumor progression; and overall survival (OS), for which death of any cause was an event.
Statistical Analysis
The probabilities of PFS and OS were calculated with a Kaplan-Meier estimator. Values for relapse/progression, TRM, and GVHD were generated with cumulative incidence estimates to account for competing risks. The EBMT and CIBMTR cohorts were combined for all the analyses after it was confirmed that all survival outcomes, TRM, and disease progression were not statistically different.
Multivariate analyses using Cox proportional hazards models for overall mortality and treatment failure (1 -PFS) were built with a forward stepwise approach. Of the 1567 patients included in the primary analysis, after the exclusion of patients without information on disease progression/relapse or death, 1523 were tested in the multivariate analysis. The analyzed covariates were as follows: data source (CIBMTR vs EBMT), age, sex, Karnofsky PS Original Article included as covariate factors in the subsequent comparisons. Proportionality assumptions were tested by the addition of a time-dependent variable.
The development of a model for the prediction of treatment failure (1 -PFS) was based on the final Cox model and included a data set with complete data on all significant covariates; all missing or unknown statuses were excluded. The Cox regression analysis was repeated in this subset cohort, and the covariates that maintained the association with the outcome were kept in the model. The cohort included 573 patients with complete information on all significant covariates: age (continuous), number of prior lines of chemotherapy (<3, 3 or 4, or 5), disease status at the time of allo-HCT (chemotherapy resistance), and Karnofsky PS (<80% vs 80%). The score was computed according to the magnitude of the effect between each significant covariate and treatment failure, and 3 risk levels were developed: low, intermediate, and high. Final probabilities for the 3 risk groups were calculated via Kaplan-Meier estimates for OS and PFS and via cumulative incidence functions for TRM and relapse/progression.
RESULTS
Patients
Patient characteristics are shown in Table 1 .
TRM
The 3-and 5-year cumulative incidences of TRM were 25% (95% confidence interval [CI], 23%-27%) and 29% (95% CI, 26%-31%), respectively (Fig. 1) . Age, chemoresistant disease, heavy pretreatment, low Karnofsky PS, and MAC regimens were associated with higher TRM in the multivariate analysis (Table 2 and Supporting Fig. 1 [see online supporting information]).
Relapse/Progression
The 3-and 5-year cumulative incidences of progression/ relapse were 17% (95% CI, 15%-19%) and 19% (95% CI, 17%-22%), respectively (Fig. 1) . Chemoresistant disease and grade 3 histology were associated with a significantly higher relapse rate after the procedure (Table 2) .
PFS
The adjusted 3-and 5-year probabilities of PFS were 58% (95% CI, 55%-60%) and 52% (95% CI, 49%-55%), respectively ( Fig. 1) . Age, grade 3 histology, chemorefractory disease, number of prior lines of therapy before transplantation, inadequate Karnofsky PS, and MAC protocols were independent adverse prognostic factors (Table 2 and Supporting Fig. 2 [see online supporting information]).
OS
The adjusted 3-and 5-year probabilities of OS were 66% (95% CI, 64%-68%) and 61% (95% CI, 59%-64%; P 5 .13), respectively (Fig. 1) . Grade 3 histology, age at transplantation, chemotherapy burden before transplantation, chemorefractory disease, poor PS, and MAC protocols were adverse prognostic factors ( Table 2 and Supporting Fig. 3 [see online supporting information]).
GVHD
The cumulative incidence of grade 2 to 4 acute GVHD at day 100 was 20% (95% CI, 18%-22%). The corresponding incidence for chronic GVHD at 1 year was 45% (95% CI, 42%-48%). The cumulative incidence of both acute and chronic GVHD was higher in the CIBMTR cohort versus the EBMT cohort in the univariate analysis (Supporting Table 1 [see online supporting information]).
Risk Score
The population used to generate the score was a subset of all patients with complete information on all significant variables tested in multivariate analyses. To assess the representativeness of this subset, the cohort (n 5 573) was compared with the excluded population, and there were no differences in OS (n 5 994; P 5 .43) or PFS (n 5 950; P 5 .13). The proposed risk score used in the model for treatment failure (1 -PFS) included the following covariates: age at HCT, number of prior chemotherapy lines, chemotherapy sensitivity, and Karnofsky PS. The score was computed with the formula in Table 3 and was used to define 3 distinct groups: 1) low-risk scores (n 5 190) ranged from 0.03 to 0.069 (mean, 0.47), 2) intermediate-risk scores (n 5 191) ranged from 0.70 to 1.05 (mean, 0.87), and 3) high-risk scores (n 5 192) ranged from 1.06 to 2.29 (mean, 1.36). The hazard ratio for the treatment failure of patients with an intermediate risk was 1 P 5 .0015) for TRM, and 1.14 (95% CI, 0.70-1.84; P 5 .60) and 0.84 (95% CI, 0.50-1.41; P 5 .51) for disease progression/relapse. Five-year PFS were 68%, 53% and 46% and 5-year OS were 80%, 62% and 50% for low, intermediate and advanced risk, respectively. Corresponding 5-year incidences of TRM were 14%, 29% and 42%, and 5-year incidences of disease progression/relapse were 18%, 18% and 12% ( Fig. 2A-D) .
DISCUSSION
The current analysis, combining the EBMT and CIBMTR experiences for a period of 10 years, represents the largest study published to date that evaluates the long- term outcomes of heavily pretreated FL patients undergoing allo-HCT. The therapeutic landscape of relapsed FL is undergoing a rapid evolution with the development of several novel agents, including phosphoinositide 3-kinase inhibitors, 15 Bruton's tyrosine kinase inhibitors, 16 and ABT-199 (NCT02187861). 17 Although auto-HCT as consolidation therapy at the time of first chemosensitive relapse/progression is able to provide long-term durable remissions in the rituximab era, a significant proportion of patients will eventually relapse. 18 Although allo-HCT is the only treatment strategy that has been demonstrated to be curative for patients with relapsed FL, its precise role and timing with the progressive incorporation of all these agents into clinical practice in the coming years need to be reevaluated.
There are significant differences in clinical practice between European and US transplant centers; the more frequent use of matched unrelated donors in the CIBMTR setting might account for the higher incidence of both acute and chronic GVHD in this cohort of patients. Despite this, the 4 major posttransplant outcomes were superimposable between the 2 registries (Supporting Table 1 [see online supporting information]). The adjusted 5-year probabilities were 52% and 52% for PFS and 62% and 61% for OS for EBMT-and CIBMTR-reported patients, respectively. These results are in line with what has already been published. [19] [20] [21] [22] [23] [24] The long-term outcomes of patients allografted from a well-matched unrelated donor are comparable to those of HLA-matched siblings. A review from the literature gives somewhat conflicting results; although a retrospective EBMT analysis 22 did not show any significant difference between the 2 donor sources, both the UK study 25 and the Fred Hutchinson Cancer Research Center experience 21 indicate that unrelated donors are associated with poorer outcomes because of higher TRM. The number of HLA mismatches may account for these differences.
Notably, the disease control achieved in this highrisk group of patients was impressive with a relapse rate of 19% at 5 years. Later relapses may yet occur, but the plateau observed in the relapse curve in this and other studies 9, 19, 20, [23] [24] [25] [26] [27] suggests that these procedures are curative treatments. Chemorefractoriness and an initial diagnosis of grade 3 FL were associated with an increased relapse/ progression rate after the procedure. The reason for the latter might have been the inclusion of patients with grade 3b FL in this series. Long-term outcomes were worse for those patients who had received more lines of therapy, had chemoresistant disease, had a poor KS status at the time of transplantation, and used a MAC protocol. These results are also in line with what has been published before [19] [20] [21] [22] [23] and indicate that patients with relapsed FL should be allografted earlier in the course of the disease. The intensity of the conditioning regimen is still a matter of debate. Although in a prior CIBMTR analysis 8 RIC protocols were associated with a higher relapse rate and lower PFS, in our analysis, MAC protocols were associated with higher TRM and lower PFS and OS. In FL, in light of the low relapse rate seen, one might favor less intense conditioning protocols to allow the disease to be cured on the basis of the clinically beneficial graft-versus lymphoma effect.
The toxicity of allo-HCT remains significant, with one-quarter of patients dying of a transplant-related complication at 3 years. The TRM rate in this study appears comparable to that reported in other studies. 19, 20, 23, 25 Strategies to further improve the prevention and management of allo-HCT-related complications are clearly required. The use of the transplant-related comorbidity index may help in identifying patients for whom the risk of allo-HCT is excessive and for whom alternative therapies may be more appropriate. 28 Finally and most importantly, the large number of patients included in the study has allowed us to construct a score that identifies clearly distinct groups of patients in terms of long-term outcomes. It is always challenging to assess the procedure-related risk of a given patient before allo-HCT because of the existence of other effective and less toxic treatment options for this histology; there are no prognostic indexes validated in this setting. The proposed score combines a patient's age, number of prior chemotherapy lines, chemotherapy sensitivity, and performance score into a 3-level risk model. Although not all these factors are modifiable, the score may assist in the clinical decision to offer allo-HCT to a given patient. Notably, allo-HCT is able to achieve an OS rate of 80% and a PFS rate higher than 60% with a 10% TRM rate in the lowrisk group of patients; these results compare favorably with those of other nontransplant therapeutic strategies. The efficacy of allo-HCT and its place in the treatment armamentarium in relation to more conventional salvage therapies and to targeted therapy remain to be elucidated. Strategies using such agents as a bridge to transplantation or alternatively as a maintenance therapy after transplantation also require further studies.
Our analysis has important limitations. During the era of this analysis, EBMT/CIBMTR case report forms did not distinguish between grade 3a and 3b histologies, but considering the fact that grade 3b is a rare histology, we anticipate grade 3b numbers to be low in the current data set. However, using the current data set, we cannot predict whether the outcomes of grade 3a FL are different from those of grade 3b FL. We excluded transformed histologies from this analysis, as determined by the reporting center (on the basis of either histological or clinical grounds). However, we cannot exclude the possibility that a few transformed cases, not recognized by the reporting center, might have been included in the current analysis. Because this analysis included cases reported to the CIBMTR at the transplant essential data level and to the EBMT at the Minimal Essential Data A level (where elaborate pre-and posttransplant therapy data are not collected), we were not able to assess the impact of pretransplant therapies, post-allo-HCT maintenance/ consolidation treatments, or chimerism kinetics on HCT outcomes. The fact that the EBMT and the CIBMTR do not collect data on patients not undergoing HCT means cost-effectiveness-type analyses are not possible with registry data sets.
In conclusion, the current analysis, albeit retrospective in nature, indicates excellent long-term outcomes for patients with relapsed FL being treated with allo-HCT and especially for those patients belonging to the low-risk group. If allo-HCT is considered a treatment option and no HLA-matched sibling donor is available, an unrelated donor search should be started in a timely manner; it has to be considered earlier in the course of the disease before the patient fails multiple lines of chemotherapy, his or her PS deteriorates, and the disease is demonstrated to be chemorefractory. MAC protocols should be avoided because of the excess toxicity.
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